{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ma YT"],"funding":["Efficacy and Mechanism Evaluation Programme","Efficacy and Mechanism Evaluation Programme (EME)"],"pagination":["3412-3423"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12351282"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(16)"],"pubmed_abstract":["Purpose
A previous study by our group using dendritic cells (DC) pulsed ex vivo with the lysate of the HepG2 cell line showed evidence of antigen-specific T-cell responses in some patients with advanced hepatocellular carcinoma. The ImmunoTACE trial evaluated the preliminary activity of this vaccine in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma.Patients and methods
A randomized phase II trial was conducted in three tertiary referral centers in the United Kingdom. Eligible patients were randomly assigned in a 1:1 ratio to TACE + preconditioning cyclophosphamide or to TACE + preconditioning cyclophosphamide + DC infusions. The primary endpoint was progression-free survival time using RECIST v1.1 criteri"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Addition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial."],"pmcid":["PMC12351282"],"funding_grant_id":["09/160/24"],"pubmed_authors":["Mehrzad H","Rowe AL","Webster L","Bathurst C","Punia P","Ma YT","Sylla P","Rao A","James MW","Hull D","Kirkham A","Stern N","Lowe F","Zuo J","Hussain S","Palmer D","Adams DH","Yap C","Karkhanis S","Curbishley S","Blahova M"],"additional_accession":[]},"is_claimable":false,"name":"Addition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial.","description":"Purpose
A previous study by our group using dendritic cells (DC) pulsed ex vivo with the lysate of the HepG2 cell line showed evidence of antigen-specific T-cell responses in some patients with advanced hepatocellular carcinoma. The ImmunoTACE trial evaluated the preliminary activity of this vaccine in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma.Patients and methods
A randomized phase II trial was conducted in three tertiary referral centers in the United Kingdom. Eligible patients were randomly assigned in a 1:1 ratio to TACE + preconditioning cyclophosphamide or to TACE + preconditioning cyclophosphamide + DC infusions. The primary endpoint was progression-free survival time using RECIST v1.1 criteri","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-05-29T14:26:05.888Z","creation":"2026-04-08T05:03:05.274Z"},"accession":"S-EPMC12351282","cross_references":{"pubmed":["40499144"],"doi":["10.1158/1078-0432.CCR-25-0142"]}}